Agencourt offers single pass DNA sequencing of plasmids and PCR¹ amplicons. This service is fueled by our high performance DNA sequencing pipeline that processes over 20 million Phred20 bases per day. The key benefits we offer our single pass DNA sequencing service customers are:

• Rapid Turnaround
• High-throughput Capacity
• Long Read Lengths
• Large Number of Phred20 Bases/Read
• High Sequencing Pass Rates

 Learn more about our DNA Sequencing Pipeline

Superior Performance Clients can expect high quality DNA sequencing results. Our typical pass rates are greater than 90% and our average Phred20 read lengths are greater than 600 bases. Our completely automated pipeline eliminates human error, providing the highest quality DNA sequencing data in the industry. Single Pass DNA Sequencing Includes: Template purification of plasmids or PCR amplicons using Agencourt SPRI® technology DNA sequencing reactions with BigDye Terminator v3.1 Dye terminator removal using Agencourt CleanSEQ reagent Sequence delineation on an ABI PRISM 3730xl Base calling and data compilation Data delivery via secure ftp site Samples Agencourt accepts single pass DNA sequencing samples as: Glycerol stocks (96 or 384-well formats) Transformed libraries Agar plated libraries Purified or unpurified PCR samples We have detailed Sample Preparation Guidelines that allow us to improve turnaround times and enable the highest level of DNA sequencing quality.

*Passing Read: Average Phred value greater than 20 for bases between 100bp and 300bp. Every phase of our DNA sequencing pipeline is fully automated, resulting in the highest throughput and lowest error rates in the industry. The photo above illustrates our automated template purification using the Agencourt SPRI technology. Results DNA sequencing results are delivered via a secure FTP site. Data delivery is personally overseen by a member of the Agencourt team to ensure simple and timely transfer. Compiled data is available in multiple file formats including: FASTA .AB1 .SCF .QUAL

¹ The PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffman-La Roche, Ltd.